Clinical Trial Update: Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A clinical trial evaluating bevacizumab with or without sunitinib in sunitinib-refractory renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sutent (sunitinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Renal Cell Carcinoma | Phase 2 | Status: WITHDRAWN